Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke
نویسندگان
چکیده
منابع مشابه
Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke.
Acute ischemic stroke (AIS) is a common cause of morbidity and mortality worldwide. Thrombolytic therapy with tissue plasminogen activator, the only approved treatment for AIS, is received by less than 2% of patients. Moreover, there is a slight increase in hemorrhagic complications with thrombolysis. Therefore, there is a need for newer therapeutic modalities in AIS, which could be used in win...
متن کاملdysphagia in acute ischemic stroke
Introduction: Swallowing dysfunction complicates acute strokes in 25-32% of cases and directly affects patientschr('39') prognosis and recovery. Dysphagia complicates the course of acute strokes through its potential of the development of chest infection, nutritional problems, and dehydration. Dysphagia is also an independent predictor of respiratory morbidity and mortality in acute stroke. In...
متن کاملP 149: Effect of Glycoprotein IIb/IIIa Inhibition on Acute Ischemic Stroke Injuries
Ischemic stroke accounts for about 87 percent of all cases. It occurs as a result of an obstruction within a vessel of the brain and sudden loss of blood circulation to the corresponding area resulting in the loss of brain function. It is caused by thrombotic or embolic occlusion of an artery and is more common than hemorrhagic stroke. We know that most of the injuries after an acute ischemic s...
متن کاملO10: Thrombo-Inflammation in Acute Ischemic Stroke
Ischemic stroke has been classified as a merely thrombotic disease, so the main goal of its treatment is the recanalization of the occluded vasculature. However, despite fast restoration of blood circulation, progressive stroke still develops in many patients, which has led to the concept of reperfusion injury. The underlying mechanism is only partly known. Though, it is accepted now, tha...
متن کاملOptimal platelet inhibition following acute ischemic stroke.
hibitor following stroke, nor do we know the appropriate loading regimen or dosage interval to maximize platelet inhibition and patient outcome. The same problem exists with platelet inhibition for secondary stroke prevention following TIA. The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, comparing clopidogrel (600 mg load followed by 75 mg daily) with aspiri...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology India
سال: 2008
ISSN: 0028-3886
DOI: 10.4103/0028-3886.44571